Telomir Pharmaceuticals (TELO)
Develops an oral small-molecule candidate for advanced triple-negative breast cancer.
$1.13
At close+0.03 (+2.73%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions27 holders · as of Mar 31, 2026 | 3.26% | 2.24M shares | |
| Insiders1 holder · as of Apr 24, 2026 | 10.64% | 7.32M shares | |
| Strategic holders1 holder · as of Oct 3, 2025 | 5.12% | 3.52M shares | |
| Otherremainder | 80.98% | 55.69M shares |
68.77M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
27 holders · 2.24M shares · 5 new positions · 10 increased · 3 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 995.4K | 1.45% | +995.4Knew | May 15, 2026 |
| BlackRock, Inc. | 289.2K | 0.42% | +3.7K | May 13, 2026 |
| Geode Capital Management, LLC | 249.1K | 0.36% | +25.5K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 135.5K | 0.20% | +135.5Knew | May 8, 2026 |
| Millennium Management LLC | 129.1K | 0.19% | −37.9K | May 15, 2026 |
| State Street Corp | 58.6K | 0.09% | 0 | May 15, 2026 |
| Bank of New York Mellon Corp | 51.5K | 0.07% | 0 | May 5, 2026 |
| Suncoast Equity Management | 51.2K | 0.07% | 0 | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 9.44% | 3.25M | 13G | Feb 12, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.